Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
Hassan
M N
MN
Parkinson's Disease Research Laboratory, Ottawa Civic Hospital, Ontario, Canada.
Thakar
J H
JH
Grimes
J D
JD
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D003342:Corpus Striatum / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008928:Mitochondria / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D010085:Oxidative Phosphorylation / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects
D011725:Pyridines; D011954:Receptors, Dopamine; C058324:2-phenylpyridine; C051448:4-phenylpyridine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine